Abstract 1574238: Intratumoral INT230-6 (Cisplatin, Vinblastine, Shao) Alone or with Ipilimumab Prolonged Survival with Favorable Safety and Immune Activation in Adults with Refractory Sarcomas (NCT 03058289) -November 02, 2023 at 10:37 am EDT

Abstract 1574238: INTRATUMORAL INT230-6 ALONE OR WITH IPILIMUMAB PROLONGED SURVIVAL WITH FAVORABLE


SAFETY AND IMMUNE ACTIVATION IN ADULTS WITH...

Related Keywords

Toronto ,Ontario ,Canada ,Westport ,Pennsylvania ,United States ,New York ,Houston ,Texas ,Fox Chase Cancer Center ,Philadelphia ,Anthonyb El Khoueiry ,Anthonyj Olszanski ,Ianb Walters ,Los Angeles ,Lillianl Siu ,Dianal Hanna ,Christian Frederick Meyer ,Matthew Ingham ,Jacob Stephen Thomas ,Albiruni Ryan Abdul Razak ,Lewish Bender ,Luish Camacho ,Nilofer Saba Azaz ,Giles Francis Whalen ,University Health Network ,Princess Margaret Cancer Centre ,University Of Massachusetts Memorial Medical Center ,Norris Comprehensive Cancer Center ,Columbia University Irving Medical Center ,Johns Hopkins Sidney Kimmel Comprehensive Cancer Center ,University Of Southern California ,Intensity Therapeutics Inc ,Ryan Abdul Razak ,Hopkins Sidney Kimmel Comprehensive Cancer Center ,University Irving Medical Center ,Comprehensive Cancer Center ,Southern California ,Massachusetts Memorial Medical Center ,Blood Disorders ,Chase Cancer Center ,Margaret Cancer Centre ,Outcome Measures ,Intensity Therapeutics ,Emergent Adverse Events ,Considered Related To Drug Regimen ,Sarcoma Treated Population ,Study Drug ,Least One ,Royal Marsden Hospital ,Markets ,